EMBO Molecular Medicine is the top open access journal in the field of experimental medicine dedicated to science at the interface between translational and clinical research and basic life sciences. We welcome original studies performed in cells and/or animals provided that they demonstrate evident human disease relevance. We encourage submissions of first-in-human studies and analyses of patient samples.

The journal is one of four EMBO Press journals run by in-house professional scientific editors. EMBO Molecular Medicine is supported by our academic Chief Editor, Prof. Philippe Sansonetti, nine academic Senior Editors and our broad and diverse advisory editorial board (https://www.embopress.org/page/journal/17574684/editors). Our journal is editorially independent of its publisher Wiley. For further details on our relationship to other EMBO Press publications, please see below.

EMBO Molecular Medicine publishes research papers as full-length Articles, short Reports and Resource articles. In addition, the journal publishes Editorials and Reviews in innovative formats that target a broad and non-specialized audience, as well as News & Views, Opinions and Commentaries.

Areas covered include, but are not limited to:

• Vascular and cardiovascular biology
• Infectious diseases and microbiome
• Endocrinology and metabolic diseases
• Stem cells and regenerative medicine
• Systems medicine and clinical genomics
• Aging
• Neurodegeneration, neurological diseases 
• Myopathies
• Gene and cell therapy
• Human genetics, autoimmunity, rare diseases
• Immunology, inflammation and vaccines
• Oncology
• Molecular diagnostics, biomarkers and imaging
• Drug discovery
• Pain and sensory defects
• Mitochondrial diseases
• Gastroenterology
• Nephrology
• Respiratory diseases
• Reproductive medicine